Strongbridge Biopharma plc to Present at Upcoming 2020 Solebury Trout Virtual Global Healthcare Conference Series

Rhea-AI Summary

Strongbridge Biopharma (Nasdaq: SBBP) announced that its management team will present at the Solebury Trout Virtual Global Healthcare Conference on May 26, 2020, at 12:00 p.m. EDT. The presentation aims to highlight the company's focus on developing therapies for rare diseases with significant unmet needs. Attendees can access the live webcast and archived presentation on the company's Investor Relations website. Notably, Strongbridge's product lineup includes RECORLEV®, currently in Phase 3 studies for Cushing’s syndrome, and KEVEYIS®, the first FDA-approved treatment for certain forms of periodic paralysis.

DUBLIN, Ireland and TREVOSE, Pa., May 18, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the management team will present at the upcoming Solebury Trout Virtual Global Healthcare Conference Series. Details are as follows:

Date/Time: Tuesday, May 26, 2020 at 12:00 p.m. EDT

To access the presentation, please login here: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/38244/indexl.html

The Company’s presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV^® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS^® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com

Investor Relations
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com

FAQ

What is the date of Strongbridge Biopharma's presentation at the Solebury Trout conference?

Strongbridge Biopharma's presentation is scheduled for May 26, 2020, at 12:00 p.m. EDT.

Where can I access the live presentation of Strongbridge Biopharma?

The live presentation can be accessed via the company's Investor Relations website or directly through the provided webcast link.

What therapies does Strongbridge Biopharma focus on developing?

Strongbridge Biopharma focuses on therapies for rare diseases with significant unmet needs, including RECORLEV® and KEVEYIS®.

What is the stock symbol for Strongbridge Biopharma?

The stock symbol for Strongbridge Biopharma is SBBP.

Is RECORLEV® involved in clinical studies?

Yes, RECORLEV® is currently being studied in Phase 3 clinical trials for the treatment of endogenous Cushing’s syndrome.